Register Now for a ATS Webinar on September 21

Improving ILD Diagnosis in a Multidisciplinary Discussion Team Incorporating a Genomic Classifier

September 21, 2023 | 5:00 – 6:00 PM ET

This is a non-CME event and does not qualify for CE or MOC credit.

Explore new data presented on the impact of the Envisia Genomic Classifier on identifying patients with ILD whose disease may progress. This can potentially prompt treatment Interventions to decrease the rate of progression.

CHEST Webinar

Presented by: Anna Podolanczuk, MD, MS and Sandeep Bansal, MD, FCCP, FACP

An accurate Interstitial Lung Disease (ILD) diagnosis is important to guide prognosis and treatment. ILD is frequently challenging to diagnose particularly when a clear answer is not available on high resolution CT. In this webinar, speakers will discuss updated IPF/PPF guidelines, key utility data, and the role of the Envisia Genomic Classifier in the diagnosis and prognosis of ILD. New data will be presented that demonstrates how the Envisia Classifier can predict clinical progression in fibrotic ILD.
Logo for Envisia Genomic Classifier

Envisia detects genomic UIP pattern to improve ILD diagnostic and prognostic confidence.

Logo for Percepta Lung Cancer Diagnostics portfolio

Percepta GSC stratifies the risk of lung cancer to guide patient management for when bronchoscopy is inconclusive.


Percepta Nasal Swab brings genomic objectivity to lung nodule risk assessment with a simple, non-invasive tool.

Transform uncertainty into confidence

Veracyte offers a suite of actionable genomic tests that can offer greater confidence and clarity at every step of your lung cancer and interstitial lung disease patient management.